Stirring up conflicts in tumour cells
Neuroblastomas are malignant solid tumors that occur mainly in early childhood. They arise from degenerated immature cells of the sympathetic nervous system.
Feb 11, 2021
0
25
Neuroblastomas are malignant solid tumors that occur mainly in early childhood. They arise from degenerated immature cells of the sympathetic nervous system.
Feb 11, 2021
0
25
Mutations that inactivate the ARID1A gene in ovarian cancer increase utilization of the glutamine amino acid making cancer cells dependent on glutamine metabolism, according to a study by The Wistar Institute published online ...
Jan 11, 2021
0
66
A new study has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.
Jan 11, 2021
0
153
The healing process that follows a brain injury could spur tumor growth when new cells generated to replace those lost to the injury are derailed by mutations, Toronto scientists have found. A brain injury can be anything ...
Jan 4, 2021
0
173
Breast cancer, the second most common cancer in the United States, can result from a number of cellular misregulations, such as deficiencies in the DNA-repairing breast cancer gene, BRCA. Typically, BRCA-associated breast ...
Dec 18, 2020
0
53
Treatments that harness the immune system to fight cancer have greatly improved outcomes for some people with cancer. Scientists are learning more about why some people respond much better than others to these drugs.
Dec 1, 2020
0
71
The labyrinth of jumbled blood vessels in the tumor microenvironment remains one of the toughest blockades for cellular therapies to penetrate and treat solid tumors. Now, in a new study published online today in Nature Cancer, ...
Nov 30, 2020
0
36
Scientists are beginning to unravel one of the biggest challenges with immunotherapy: why some people with cancer respond to the treatment, while others may not respond at all.
Nov 16, 2020
0
108
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic ...
Nov 16, 2020
0
47
Cancer Research UK scientists have invented a new experimental drug that aims to harness the full power of the body's own immune system, launching a two-pronged response against cancer, according to a study published in Nature ...
Nov 10, 2020
0
147